Neurobiological pathways to Alzheimer's disease: Amyloid-beta, TAU protein or both?
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Abstract Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive decline, including memory loss, behavioral and psychological symptoms and personality changes. The neuropathological hallmarks of AD are the presence of neuritic (senile) plaques (NP) and neurofibrillary tangles (NFT), along with neuronal loss, dystrophic neurites, and gliosis. Neuritic plaques are extracellular lesions and their main constituent is the amyloid-b42 peptide (Ab42). Neurofibrillary tangles are intracellular lesions that are mainly composed of hyperphosphorylated TAU protein. In this article, we review the major hypotheses concerning the physiopathology of AD, focusing on the b-amyloid cascade as primary events (supported by the "baptists") and cytoskeletal abnormalities secondary to the hyperphosphorylation of protein TAU (as advocated by the "Tauists"). We further provide an integrative view of the physiopathology of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 2×
“Since late-onset AD (LOAD) represents the vast majority of cases, and considering that amyloidogenesis in these patients occurs to a lesser extent compared to the early AD, questions have been raised concerning the appropriateness of EOAD models to aid understanding of LOAD.42”
Tau pathology in Alzheimer disease and other tauopathies
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., Khatoon, S., Li, B., Liu, F., Rahman, A., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.008 · Cited by 1,037 · cited 1×
“Dynamic changes in the phosphorylation state of TAu occur in mechanisms involved in neuronal remodeling and synaptic plasticity.(32) under pathological conditions, including the pathophysiology of AD, TAu can be abnormally hyperphosphorylated, which impairs its capacity to bind to tubulin, leading to destabilization o…”
Phosphorylation affects the ability of tau protein to promote microtubule assembly.
Lindwall, G., & Cole, R. D. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42989-9 · Cited by 901
Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500466102 · Cited by 709 · cited 11×
“One interesting study in human leukocytes showed that peripheral GSK3β activity is increased in AD.55 Such converging evidence support the “GSK3β hypothesis” in AD,56 according to which, the deregulation of GSK3β metabolism leading to increased activity is an early pathological event in the pathophysiology of AD, trig…”
InfluentialTau phosphorylation in neuronal cell function and dysfunction
Johnson, G. V. W., & Stoothoff, W. H. (2004) · Journal of Cell Science · doi:10.1242/jcs.01558 · Cited by 624
Roberts, G. W., Gentleman, S. M., Lynch, A., Murray, L., Landon, M., & Graham, D. I. (1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.4.419 · Cited by 569 · cited 1×
“The cleavage of APP by α-secretase occurs within the region that contains the Aβ peptide, precluding the formation of this peptide.(9) Alternatively, APP may be cleaved by β-secretase releasing a smaller N-terminal fragment (sAPPβ) and a C-terminal fragment (C99) that produces the full-length β-amyloid peptides (Aβ) u…”
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases
Mazanetz, M. P., & Fischer, P. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2111 · Cited by 459 · cited 2×
“been described in AD,(41) constituting a marker of neuronal degeneration in this disorder.(45) The abnormal phosphorylation of TAu in serine/threonine residues near the tubulin binding domain favors disaggregation of the TAu-tubulin complex and the reassembly of TAu into PHFs, giving rise to NFT formation.”
Structural Principles of Tau and the Paired Helical Filaments of Alzheimer's Disease
Mandelkow, E., Von Bergen, M., Biernat, J., & Mandelkow, E. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00053.x · Cited by 243 · cited 3×
“, 2007).(46) At least 25 abnormal phosphorylation sites have”
Influential
Cited by
Lamptey, R. N. L., Chaulagain, B., Trivedi, R., Gothwal, A., Layek, B., & Singh, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031851 · Cited by 900
Tau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development
Mueed, Z., Tandon, P., Maurya, S. K., Deval, R., Kamal, M. A., & Poddar, N. K. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01017 · Cited by 111
The informed road map to prevention of Alzheimer Disease: a call to arms
McDade, E., Llibre-Guerra, J. J., Holtzman, D. M., Morris, J. C., & Bateman, R. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00467-y · Cited by 89
Ciccone, L., Shi, C., di Lorenzo, D., Van Baelen, A.-C., & Tonali, N. (2020) · Molecules · doi:10.3390/molecules25102439 · Cited by 69
“Others, instead, support the idea that it is mainly Tau that plays the major role in the etiopathology, essentially for two reasons: firstly because Tau tangles can be found in patients’ brain even when extracellular Aβ deposits are not present [57], and secondly because evidences proved that intracellular Tau tangles…”
BackgroundWW domain-containing oxidoreductase in neuronal injury and neurological diseases
Chang, H.-T., Liu, C.-C., Chen, S.-T., Yap, Y. V., Chang, N.-S., & Sze, C.-I. (2014) · Oncotarget · doi:10.18632/oncotarget.2961 · Cited by 41
Metadata
- Authors
- Paula, V. D. J. R. D., Guimarães, F. M., Diniz, B. S., & Forlenza, O. V.
- Venue
- Dementia & Neuropsychologia
- Publisher
- FapUNIFESP (SciELO)
- Published
- 2009-09
- Volume
- 3
- Issue
- 3
- Pages
- 188-194
- ISSN
- 1980-5764 (ISSN-L)
- OpenAlex
- W2116387197
- Cited by
- 155
- References
- 11
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neurobiological pathways to Alzheimer's disease: Amyloid-beta, TAU protein or both? https://app.cochat.ai/papers/10.1590/s1980-57642009dn30300003
- The paper
- Paula, V. D. J. R. D., Guimarães, F. M., Diniz, B. S., & Forlenza, O. V. (2009). Neurobiological pathways to Alzheimer's disease: Amyloid-beta, TAU protein or both? Dementia & Neuropsychologia. https://doi.org/10.1590/s1980-57642009dn30300003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.